PeptideScanner retained ClinicalTrials.gov record NCT02059460 at 2026-11-15T21:47:40.408Z. Its registry update date was 2016-12-15, and PeptideScanner's reviewed identity mapping was terlipressin.
PeptideScanner retained ClinicalTrials.gov record NCT00002779 at 2026-07-30T21:34:56.506Z. Its registry update date was 2016-12-15, and PeptideScanner's reviewed identity mapping was octreotide.
PeptideScanner retained ClinicalTrials.gov record NCT00928434 at 2026-07-30T21:34:56.510Z. Its registry update date was 2016-12-13, and PeptideScanner's reviewed identity mapping was leuprolide.
PeptideScanner retained ClinicalTrials.gov record NCT01750398 at 2026-07-30T21:34:56.506Z. Its registry update date was 2016-12-05, and PeptideScanner's reviewed identity mapping was leuprolide.
PeptideScanner retained ClinicalTrials.gov record NCT01309399 at 2026-07-30T21:34:56.507Z. Its registry update date was 2016-11-23, and PeptideScanner's reviewed identity mapping was teriparatide.
PeptideScanner retained ClinicalTrials.gov record NCT01971242 at 2026-07-30T21:34:56.502Z. Its registry update date was 2016-11-17, and PeptideScanner's reviewed identity mapping was exenatide.
PeptideScanner retained ClinicalTrials.gov record NCT02313220 at 2026-07-30T21:34:56.513Z. Its registry update date was 2016-11-17, and PeptideScanner's reviewed identity mapping was exenatide.
PeptideScanner retained ClinicalTrials.gov record NCT02569502 at 2026-11-16T01:41:15.051Z. Its registry update date was 2016-11-02, and PeptideScanner's reviewed identity mapping was enfuvirtide.
PeptideScanner retained ClinicalTrials.gov record NCT01500863 at 2026-11-15T21:49:16.513Z. Its registry update date was 2016-10-26, and PeptideScanner's reviewed identity mapping was triptorelin.
PeptideScanner retained ClinicalTrials.gov record NCT00804336 at 2026-11-15T22:05:38.400Z. Its registry update date was 2016-10-19, and PeptideScanner's reviewed identity mapping was pasireotide.
PeptideScanner retained ClinicalTrials.gov record NCT01457430 at 2026-11-15T22:04:12.435Z. Its registry update date was 2016-10-18, and PeptideScanner's reviewed identity mapping was icatibant.
PeptideScanner retained ClinicalTrials.gov record NCT01782261 at 2026-07-30T21:34:56.513Z. Its registry update date was 2016-10-11, and PeptideScanner's reviewed identity mapping was liraglutide.
PeptideScanner retained ClinicalTrials.gov record NCT01444898 at 2026-07-30T21:36:16.906Z. Its registry update date was 2016-09-29, and PeptideScanner's reviewed identity mapping was exenatide.
PeptideScanner retained ClinicalTrials.gov record NCT01478971 at 2026-11-16T17:45:11.119Z. Its registry update date was 2016-09-20, and PeptideScanner's reviewed identity mapping was peginesatide.
PeptideScanner retained ClinicalTrials.gov record NCT01076335 at 2026-07-30T21:36:16.908Z. Its registry update date was 2016-09-19, and PeptideScanner's reviewed identity mapping was leuprolide.
PeptideScanner retained ClinicalTrials.gov record NCT00701636 at 2026-11-15T22:01:45.056Z. Its registry update date was 2016-08-29, and PeptideScanner's reviewed identity mapping was daptomycin.
PeptideScanner retained ClinicalTrials.gov record NCT02478879 at 2026-07-30T21:36:16.907Z. Its registry update date was 2016-08-23, and PeptideScanner's reviewed identity mapping was teriparatide.
PeptideScanner retained ClinicalTrials.gov record NCT01620138 at 2026-11-15T22:05:38.400Z. Its registry update date was 2016-08-22, and PeptideScanner's reviewed identity mapping was pasireotide.
PeptideScanner retained ClinicalTrials.gov record NCT00025883 at 2026-11-16T17:35:38.955Z. Its registry update date was 2016-08-16, and PeptideScanner's reviewed identity mapping was metreleptin.
PeptideScanner retained ClinicalTrials.gov record NCT02545738 at 2026-07-30T21:36:16.908Z. Its registry update date was 2016-08-10, and PeptideScanner's reviewed identity mapping was liraglutide.
PeptideScanner retained ClinicalTrials.gov record NCT01452451 at 2026-11-16T17:34:46.889Z. Its registry update date was 2016-08-09, and PeptideScanner's reviewed identity mapping was efpeglenatide.
PeptideScanner retained ClinicalTrials.gov record NCT02075281 at 2026-11-16T17:34:46.889Z. Its registry update date was 2016-08-09, and PeptideScanner's reviewed identity mapping was efpeglenatide.
PeptideScanner retained ClinicalTrials.gov record NCT02081118 at 2026-11-16T17:34:46.889Z. Its registry update date was 2016-08-09, and PeptideScanner's reviewed identity mapping was efpeglenatide.
PeptideScanner retained ClinicalTrials.gov record NCT02160990 at 2026-07-30T21:36:16.909Z. Its registry update date was 2016-08-09, and PeptideScanner's reviewed identity mapping was exenatide.
PeptideScanner retained ClinicalTrials.gov record NCT01829516 at 2026-11-16T00:59:19.138Z. Its registry update date was 2016-07-27, and PeptideScanner's reviewed identity mapping was oxytocin.
PeptideScanner retained ClinicalTrials.gov record NCT00659373 at 2026-11-15T21:49:16.513Z. Its registry update date was 2016-07-25, and PeptideScanner's reviewed identity mapping was triptorelin.
PeptideScanner retained ClinicalTrials.gov record NCT00812370 at 2026-11-15T21:58:19.888Z. Its registry update date was 2016-07-15, and PeptideScanner's reviewed identity mapping was bivalirudin.
PeptideScanner retained ClinicalTrials.gov record NCT01204476 at 2026-07-30T21:36:16.909Z. Its registry update date was 2016-07-15, and PeptideScanner's reviewed identity mapping was octreotide.
PeptideScanner retained ClinicalTrials.gov record NCT00206297 at 2026-07-30T21:36:16.909Z. Its registry update date was 2016-07-14, and PeptideScanner's reviewed identity mapping was pramlintide.
PeptideScanner retained ClinicalTrials.gov record NCT00033605 at 2026-07-30T21:36:16.907Z. Its registry update date was 2016-07-13, and PeptideScanner's reviewed identity mapping was octreotide.
PeptideScanner retained ClinicalTrials.gov record NCT02582983 at 2026-11-16T01:41:15.051Z. Its registry update date was 2016-07-06, and PeptideScanner's reviewed identity mapping was enfuvirtide.
PeptideScanner retained ClinicalTrials.gov record NCT00757185 at 2026-11-15T22:03:26.540Z. Its registry update date was 2016-07-04, and PeptideScanner's reviewed identity mapping was ganirelix.
PeptideScanner retained ClinicalTrials.gov record NCT01816321 at 2026-11-15T22:03:26.540Z. Its registry update date was 2016-06-23, and PeptideScanner's reviewed identity mapping was ganirelix.
PeptideScanner retained ClinicalTrials.gov record NCT00451204 at 2026-11-16T17:42:50.457Z. Its registry update date was 2016-06-16, and PeptideScanner's reviewed identity mapping was glatiramer-acetate.
PeptideScanner retained ClinicalTrials.gov record NCT02784457 at 2026-11-15T22:02:39.332Z. Its registry update date was 2016-05-27, and PeptideScanner's reviewed identity mapping was cetrorelix.
PeptideScanner retained ClinicalTrials.gov record NCT00943956 at 2026-07-30T21:37:20.823Z. Its registry update date was 2016-05-25, and PeptideScanner's reviewed identity mapping was leuprolide.
PeptideScanner retained ClinicalTrials.gov record NCT01951651 at 2026-07-30T21:37:20.824Z. Its registry update date was 2016-05-16, and PeptideScanner's reviewed identity mapping was exenatide.
PeptideScanner retained ClinicalTrials.gov record NCT01076764 at 2026-11-15T21:59:29.646Z. Its registry update date was 2016-05-04, and PeptideScanner's reviewed identity mapping was eptifibatide.
PeptideScanner retained ClinicalTrials.gov record NCT02757703 at 2026-11-15T21:47:40.408Z. Its registry update date was 2016-05-03, and PeptideScanner's reviewed identity mapping was terlipressin.
PeptideScanner retained ClinicalTrials.gov record NCT02276196 at 2026-07-30T21:37:20.821Z. Its registry update date was 2016-04-29, and PeptideScanner's reviewed identity mapping was lixisenatide.
PeptideScanner retained ClinicalTrials.gov record NCT00903162 at 2026-07-30T21:37:20.822Z. Its registry update date was 2016-04-18, and PeptideScanner's reviewed identity mapping was leuprolide.
PeptideScanner retained ClinicalTrials.gov record NCT00241020 at 2026-07-30T21:37:20.823Z. Its registry update date was 2016-04-12, and PeptideScanner's reviewed identity mapping was octreotide.
PeptideScanner retained ClinicalTrials.gov record NCT01432405 at 2026-07-30T21:37:20.822Z. Its registry update date was 2016-04-12, and PeptideScanner's reviewed identity mapping was exenatide.
PeptideScanner retained ClinicalTrials.gov record NCT02733419 at 2026-11-16T01:41:15.051Z. Its registry update date was 2016-04-11, and PeptideScanner's reviewed identity mapping was enfuvirtide.
PeptideScanner retained ClinicalTrials.gov record NCT00790062 at 2026-11-16T00:59:19.138Z. Its registry update date was 2016-04-08, and PeptideScanner's reviewed identity mapping was oxytocin.
PeptideScanner retained ClinicalTrials.gov record NCT01488487 at 2026-11-15T22:05:38.400Z. Its registry update date was 2016-04-07, and PeptideScanner's reviewed identity mapping was pasireotide.
PeptideScanner retained ClinicalTrials.gov record NCT01848899 at 2026-11-15T21:58:19.888Z. Its registry update date was 2016-04-06, and PeptideScanner's reviewed identity mapping was bivalirudin.
PeptideScanner retained ClinicalTrials.gov record NCT01483651 at 2026-07-30T21:38:42.855Z. Its registry update date was 2016-03-29, and PeptideScanner's reviewed identity mapping was glucagon.
PeptideScanner retained ClinicalTrials.gov record NCT00586898 at 2026-11-15T21:50:32.222Z. Its registry update date was 2016-03-25, and PeptideScanner's reviewed identity mapping was goserelin.
PeptideScanner retained ClinicalTrials.gov record NCT01237119 at 2026-07-30T21:38:42.856Z. Its registry update date was 2016-03-23, and PeptideScanner's reviewed identity mapping was liraglutide.
PeptideScanner retained ClinicalTrials.gov record NCT01265875 at 2026-11-16T01:34:15.953Z. Its registry update date was 2016-03-09, and PeptideScanner's reviewed identity mapping was secretin.
PeptideScanner retained ClinicalTrials.gov record NCT00434148 at 2026-11-15T22:05:38.400Z. Its registry update date was 2016-03-08, and PeptideScanner's reviewed identity mapping was pasireotide.
PeptideScanner retained ClinicalTrials.gov record NCT01667900 at 2026-07-30T21:38:42.858Z. Its registry update date was 2016-03-07, and PeptideScanner's reviewed identity mapping was dulaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT00628160 at 2026-11-15T21:47:40.408Z. Its registry update date was 2016-02-24, and PeptideScanner's reviewed identity mapping was terlipressin.
PeptideScanner retained ClinicalTrials.gov record NCT02099084 at 2026-11-15T21:55:23.600Z. Its registry update date was 2016-02-22, and PeptideScanner's reviewed identity mapping was teduglutide.
PeptideScanner retained ClinicalTrials.gov record NCT00022763 at 2026-11-16T01:41:15.051Z. Its registry update date was 2016-02-15, and PeptideScanner's reviewed identity mapping was enfuvirtide.
PeptideScanner retained ClinicalTrials.gov record NCT01087723 at 2026-11-15T21:58:19.888Z. Its registry update date was 2016-02-12, and PeptideScanner's reviewed identity mapping was bivalirudin.
PeptideScanner retained ClinicalTrials.gov record NCT00454571 at 2026-07-30T21:38:42.855Z. Its registry update date was 2016-02-10, and PeptideScanner's reviewed identity mapping was leuprolide.
PeptideScanner retained ClinicalTrials.gov record NCT01121939 at 2026-07-30T21:38:42.856Z. Its registry update date was 2016-02-05, and PeptideScanner's reviewed identity mapping was octreotide.
PeptideScanner retained ClinicalTrials.gov record NCT01511016 at 2026-11-16T17:35:38.955Z. Its registry update date was 2016-01-27, and PeptideScanner's reviewed identity mapping was metreleptin.
PeptideScanner retained ClinicalTrials.gov record NCT02333253 at 2026-11-15T22:02:39.332Z. Its registry update date was 2016-01-27, and PeptideScanner's reviewed identity mapping was cetrorelix.
PeptideScanner retained ClinicalTrials.gov record NCT01861015 at 2026-11-15T22:08:31.832Z. Its registry update date was 2016-01-22, and PeptideScanner's reviewed identity mapping was vasopressin.
PeptideScanner retained ClinicalTrials.gov record NCT01977456 at 2026-11-15T21:59:29.646Z. Its registry update date was 2016-01-21, and PeptideScanner's reviewed identity mapping was eptifibatide.
PeptideScanner retained ClinicalTrials.gov record NCT01874145 at 2026-11-16T17:42:50.457Z. Its registry update date was 2016-01-14, and PeptideScanner's reviewed identity mapping was glatiramer-acetate.
PeptideScanner retained ClinicalTrials.gov record NCT02646189 at 2026-11-15T22:10:40.222Z. Its registry update date was 2016-01-05, and PeptideScanner's reviewed identity mapping was thymosin-alpha-1.